A collection of algorithms for detecting pulmonary arterial hypertension in administrative data has been developed to enhance the integrity and value of research findings and improve quality of care.
Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
Low-risk status is unattainable for most patients with pulmonary arterial hypertension, and the first year from diagnosis is important in defining the longitudinal risk status.
Physicians frequently underestimate or overestimate disease progression risk in patients with World Health Organization functional class II pulmonary arterial hypertension.
The purpose of this study was to determine whether baseline pulmonary hypertension influences the outcome of transcatheter mitral valve repair (TMVr) in patients presenting with HF with SMR.
Transthoracic echocardiography may overestimate pulmonary arterial pressure in multiple patient populations and cannot replace right heart catheterization as a confirmatory tool.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
The 6th WSPH Task Force on Hemodynamic Definitions and Clinical Classification recently proposed reducing the diagnostic mPAP threshold for pulmonary hypertension.
Elevated levels of circulating IGFBP2 were found to be associated with PAH severity and mortality.
Adult patients with pulmonary arterial hypertension (PAH) who were also obese had worse disease-specific health-related quality of life compared to patients of normal weight.
